Status:

RECRUITING

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Lead Sponsor:

Reunion Neuroscience Inc

Conditions:

Adjustment Disorder

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

Eligibility Criteria

Inclusion

  • Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF
  • Is sufficiently ambulatory and capable of self care as necessary to complete study procedures
  • Has normal cognitive function
  • Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study
  • If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant
  • Is willing and able to comply with the conditions and requirements of the study

Exclusion

  • Has a significant risk of suicide
  • Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
  • Has active or a history of central nervous system malignancy
  • Has other medically significant conditions rendering unsuitability for the study
  • Has used or will need to use prohibited medications or therapies
  • Has a known sensitivity or intolerance to study intervention or potential rescue medications

Key Trial Info

Start Date :

July 30 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT07002034

Start Date

July 30 2025

End Date

December 1 2026

Last Update

December 15 2025

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

UAB, Psychiatry and Behavioral Neurology

Birmingham, Alabama, United States, 35209

2

University of Arizona

Tucson, Arizona, United States, 85724

3

Kadima Neuropsychiatry Institute

San Diego, California, United States, 92037

4

Providence Medical Foundation

Santa Rosa, California, United States, 95403